Kalytera Therapeutics
Curated by SignalDeveloper of cannabinoid therapies for osteoporosis and bone healing
Overview
Kalytera Therapeutics is a developer of cannabinoid therapies for osteoporosis and bone healing. It focused on developing a portfolio of cannabinoid therapies with initial work on non-psychoactive cannabinoid and endocannabinoid-like medicines. It is currently working on commercializing its proprietary synthetic cannabinoid therapies across a range of disease states with an initial focus on osteoporosis and bone healing. Its lead product KAL671, synthetic fatty acid amide and an endocannabinoid-like molecule licensed from Yissum Research Development Company restore bone in persons suffering from osteoporosis are in the research phase.
Key facts
- Founded
- 2014
- Headquarters
- San Rafael, United States
- Stage
- Sign up to view
- Industry
- Health Technology
Contact
- Primary office
- Sign up to view
- Sign up to view
- Phone
- Sign up to view